-
Je něco špatně v tomto záznamu ?
The treatment with sGC stimulator improves survival of hypertensive rats in response to volume-overload induced by aorto-caval fistula
O. Gawrys, Z. Husková, P. Škaroupková, Z. Honetschlägerová, Z. Vaňourková, S. Kikerlová, V. Melenovský, BS. Bačová, M. Sykora, M. Táborský, L. Červenka
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 2013-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2013-01-01 do Před 1 rokem
- MeSH
- guanosinmonofosfát cyklický metabolismus MeSH
- guanylátcyklasa MeSH
- hypertenze * farmakoterapie MeSH
- kardiorenální syndrom * MeSH
- krysa rodu rattus MeSH
- lidé MeSH
- oxid dusnatý metabolismus MeSH
- píštěle * MeSH
- potkani transgenní MeSH
- rozpustná guanylátcyklasa metabolismus MeSH
- srdeční selhání * farmakoterapie MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Heart failure (HF) has been declared as global pandemic and current therapies are still ineffective, especially in patients that develop concurrent cardio-renal syndrome. Considerable attention has been focused on the nitric oxide (NO)/soluble guanylyl cyclase (sGC)/cyclic guanosine monophosphate (cGMP) pathway. In the current study, we aimed to investigate the effectiveness of sGC stimulator (BAY41-8543) with the same mode of action as vericiguat, for the treatment of heart failure (HF) with cardio-renal syndrome. As a model, we chose heterozygous Ren-2 transgenic rats (TGR), with high-output heart failure, induced by aorto-caval fistula (ACF). The rats were subjected into three experimental protocols to evaluate short-term effects of the treatment, impact on blood pressure, and finally the long-term survival lasting 210 days. As control groups, we used hypertensive sham TGR and normotensive sham HanSD rats. We have shown that the sGC stimulator effectively increased the survival of rats with HF in comparison to untreated animals. After 60 days of sGC stimulator treatment, the survival was still 50% compared to 8% in the untreated rats. One-week treatment with sGC stimulator increased the excretion of cGMP in ACF TGR (109 ± 28 nnmol/12 h), but the ACE inhibitor decreased it (-63 ± 21 nnmol/12 h). Moreover, sGC stimulator caused a decrease in SBP, but this effect was only temporary (day 0: 117 ± 3; day 2: 108 ± 1; day 14: 124 ± 2 mmHg). These results support the concept that sGC stimulators might represent a valuable class of drugs to battle heart failure especially with cardio-renal syndrome, but further studies are necessary.
Department of Cardiology Institute for Clinical and Experimental Medicine Prague Czech Republic
Experimental Medicine Centre Institute for Clinical and Experimental Medicine Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000544
- 003
- CZ-PrNML
- 005
- 20240213093240.0
- 007
- ta
- 008
- 240109s2023 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00210-023-02561-y $2 doi
- 035 __
- $a (PubMed)37338578
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Gawrys, Olga $u Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. olga.gawrys@ikem.cz $1 https://orcid.org/0000000243973991
- 245 14
- $a The treatment with sGC stimulator improves survival of hypertensive rats in response to volume-overload induced by aorto-caval fistula / $c O. Gawrys, Z. Husková, P. Škaroupková, Z. Honetschlägerová, Z. Vaňourková, S. Kikerlová, V. Melenovský, BS. Bačová, M. Sykora, M. Táborský, L. Červenka
- 520 9_
- $a Heart failure (HF) has been declared as global pandemic and current therapies are still ineffective, especially in patients that develop concurrent cardio-renal syndrome. Considerable attention has been focused on the nitric oxide (NO)/soluble guanylyl cyclase (sGC)/cyclic guanosine monophosphate (cGMP) pathway. In the current study, we aimed to investigate the effectiveness of sGC stimulator (BAY41-8543) with the same mode of action as vericiguat, for the treatment of heart failure (HF) with cardio-renal syndrome. As a model, we chose heterozygous Ren-2 transgenic rats (TGR), with high-output heart failure, induced by aorto-caval fistula (ACF). The rats were subjected into three experimental protocols to evaluate short-term effects of the treatment, impact on blood pressure, and finally the long-term survival lasting 210 days. As control groups, we used hypertensive sham TGR and normotensive sham HanSD rats. We have shown that the sGC stimulator effectively increased the survival of rats with HF in comparison to untreated animals. After 60 days of sGC stimulator treatment, the survival was still 50% compared to 8% in the untreated rats. One-week treatment with sGC stimulator increased the excretion of cGMP in ACF TGR (109 ± 28 nnmol/12 h), but the ACE inhibitor decreased it (-63 ± 21 nnmol/12 h). Moreover, sGC stimulator caused a decrease in SBP, but this effect was only temporary (day 0: 117 ± 3; day 2: 108 ± 1; day 14: 124 ± 2 mmHg). These results support the concept that sGC stimulators might represent a valuable class of drugs to battle heart failure especially with cardio-renal syndrome, but further studies are necessary.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a kardiorenální syndrom $7 D059347
- 650 12
- $a hypertenze $x farmakoterapie $7 D006973
- 650 _2
- $a potkani transgenní $7 D055647
- 650 _2
- $a rozpustná guanylátcyklasa $x metabolismus $7 D000071756
- 650 12
- $a píštěle $7 D005402
- 650 12
- $a srdeční selhání $x farmakoterapie $7 D006333
- 650 _2
- $a oxid dusnatý $x metabolismus $7 D009569
- 650 _2
- $a guanosinmonofosfát cyklický $x metabolismus $7 D006152
- 650 _2
- $a guanylátcyklasa $7 D006162
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Husková, Zuzana $u Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Škaroupková, Petra $u Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Honetschlägerová, Zuzana $u Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Vaňourková, Zdeňka $u Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Kikerlová, Soňa $u Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Melenovský, Vojtěch $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Bačová, Barbara Szeiffová $u Centre of Experimental Medicine, Slovak Academy of Sciences, Institute for Heart Research, Bratislava, Slovakia
- 700 1_
- $a Sykora, Matúš $u Centre of Experimental Medicine, Slovak Academy of Sciences, Institute for Heart Research, Bratislava, Slovakia
- 700 1_
- $a Táborský, Miloš $u Department of Internal Medicine I, Cardiology, University Hospital Olomouc and Palacký University, Olomouc, Czech Republic
- 700 1_
- $a Červenka, Luděk $u Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Department of Internal Medicine I, Cardiology, University Hospital Olomouc and Palacký University, Olomouc, Czech Republic
- 773 0_
- $w MED00003462 $t Naunyn-Schmiedeberg's archives of pharmacology $x 1432-1912 $g Roč. 396, č. 12 (2023), s. 3757-3773
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37338578 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093237 $b ABA008
- 999 __
- $a ok $b bmc $g 2049291 $s 1210238
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 396 $c 12 $d 3757-3773 $e 20230620 $i 1432-1912 $m Naunyn-Schmiedeberg's archives of pharmacology $n Naunyn Schmiedebergs Arch Pharmacol $x MED00003462
- LZP __
- $a Pubmed-20240109
